{"id":3173,"date":"2026-04-10T08:29:08","date_gmt":"2026-04-10T05:29:08","guid":{"rendered":"https:\/\/merkezlaboratuvari.com\/test-listesi\/igf-1-somatomedin-c-15-dk-2\/"},"modified":"2026-04-21T12:38:35","modified_gmt":"2026-04-21T09:38:35","slug":"igf-1-somatomedin-c-15-dk","status":"publish","type":"page","link":"https:\/\/merkezlaboratuvari.com\/ar\/test-listesi\/igf-1-somatomedin-c-15-dk\/","title":{"rendered":"IGF-1 ( Somatomedin C), 15. dk."},"content":{"rendered":"<h1>IGF-1 ( Somatomedin C), 15. dk.<\/h1>\n<h2>Laboratuvar Bilgileri<\/h2>\n<ul>\n<li><strong>Yeni Kod:<\/strong> BIO4140<\/li>\n<li><strong>SUT Kodu:<\/strong> L103800<\/li>\n<li><strong>Eski Kod:<\/strong> HR1140<\/li>\n<li><strong>Kategori:<\/strong> \u0643\u064a\u0645\u064a\u0627\u0621 \u062d\u064a\u0648\u064a\u0629<\/li>\n<li><strong>Numune T\u00fcr\u00fc:<\/strong> Serum<\/li>\n<li><strong>Numune Kab\u0131:<\/strong> Sar\u0131 Kapak<\/li>\n<li><strong>\u00c7al\u0131\u015fma G\u00fcn\u00fc:<\/strong> Her g\u00fcn<\/li>\n<li><strong>\u00d6nemli Kriter:<\/strong> \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.<\/li>\n<li><strong>Raporlama Tarihi:<\/strong> 2 g\u00fcn sonra 18:00<\/li>\n<\/ul>\n<h2>IGF-1 ( Somatomedin C), 15. dk. Testi Nedir?<\/h2>\n<p>IGF-1 ( Somatomedin C), 15. dk., laboratuvar ortam\u0131nda de\u011ferlendirilen bir biyokimya testidir. De\u011ferlendirme \u00e7o\u011fu zaman serum \u00f6rne\u011fi \u00fczerinden planlan\u0131r.<\/p>\n<ul>\n<li><strong>Tam Adi:<\/strong> \u0130ns\u00fclin Benzeri B\u00fcy\u00fcme Fakt\u00f6r\u00fc 1 (Somatomedin C)<\/li>\n<li><strong>Kisaltmasi:<\/strong> IGF-1 \/ IGF-I<\/li>\n<li><strong>Neyi \u00d6l\u00e7er:<\/strong> Baslik\u00e7a karacigerden, b\u00fcy\u00fcme hormonunun (GH) uyarisiyla salgilanan IGF-1&#8217;in kandaki d\u00fczeyini \u00f6l\u00e7er. IGF-1, GH&#8217;nin biyolojik etkilerinin b\u00fcy\u00fck b\u00f6l\u00fcm\u00fcn\u00fc arac\u0131l\u0131k eder ve GH aktivitesinin en g\u00fcvenilir dolayl\u0131 g\u00f6stergesidir. GH&#8217;nin aksine g\u00fcn i\u00e7inde stabil d\u00fczeylerde bulunur.<\/li>\n<\/ul>\n<p>Bu testin klinik anlam\u0131; istem nedeni, hastan\u0131n yak\u0131nmalar\u0131, ya\u015f\u0131, e\u015flik eden hastal\u0131klar\u0131, kullan\u0131lan y\u00f6ntem ve di\u011fer laboratuvar bulgular\u0131 ile birlikte de\u011ferlendirilir. Bu nedenle sonu\u00e7, tek ba\u015f\u0131na de\u011fil, b\u00fct\u00fcnc\u00fcl t\u0131bbi \u00e7er\u00e7eve i\u00e7inde yorumlanmal\u0131d\u0131r.<\/p>\n<h2>IGF-1 ( Somatomedin C), 15. dk. Hangi Durumlarda \u0130stenir?<\/h2>\n<p>IGF-1 ( Somatomedin C), 15. dk. testi, hekim taraf\u0131ndan klinik gereklilik g\u00f6r\u00fclen durumlarda istenebilir. \u0130stem gerek\u00e7esi hastan\u0131n mevcut tablosuna g\u00f6re de\u011fi\u015febilir.<\/p>\n<ul>\n<li>GH eksikligi taramasi (\u00e7ocuk ve yetiskin)<\/li>\n<li>Akromegali tanisi ve tedavi takibi<\/li>\n<li>B\u00fcy\u00fcme geriliGi arastirmasi<\/li>\n<li>GH tedavisi etkinliginin izlenmesi<\/li>\n<li>Hipopit\u00fcitarizm degerlendirmesi<\/li>\n<\/ul>\n<p>Ayn\u0131 test farkl\u0131 hastalarda farkl\u0131 klinik sorulara yan\u0131t aramak amac\u0131yla kullan\u0131labildi\u011fi i\u00e7in, nihai de\u011ferlendirme her zaman ki\u015fisel t\u0131bbi \u00f6yk\u00fc ve muayene bulgular\u0131 ile birlikte yap\u0131lmal\u0131d\u0131r.<\/p>\n<h2>IGF-1 ( Somatomedin C), 15. dk. Testi \u00d6ncesi Haz\u0131rl\u0131k<\/h2>\n<p>Haz\u0131rl\u0131k gereksinimi; testin t\u00fcr\u00fcne, numune yap\u0131s\u0131na ve laboratuvar\u0131n \u00e7al\u0131\u015fma kurallar\u0131na g\u00f6re de\u011fi\u015febilir. Test \u00f6ncesinde laboratuvar\u0131n ve hekimin verdi\u011fi talimatlar esas al\u0131nmal\u0131d\u0131r.<\/p>\n<ul>\n<li>A\u00e7lik genellikle gerekmez; ancak a\u00e7lik \u00f6nerilir.<\/li>\n<li>Herhangi bir saatte alinabilir (di\u00fcrnal varyasyon minimaldir).<\/li>\n<li>GH tedavisi alan hastalar bunu bildirmelidir.<\/li>\n<\/ul>\n<p>Kullan\u0131lan ila\u00e7lar, takviyeler, yak\u0131n d\u00f6nemde ge\u00e7irilen hastal\u0131klar ve e\u015flik eden kronik durumlar sonucun yorumlanmas\u0131n\u0131 etkileyebilece\u011fi i\u00e7in sa\u011fl\u0131k profesyoneli ile payla\u015f\u0131lmal\u0131d\u0131r.<\/p>\n<h2>IGF-1 ( Somatomedin C), 15. dk. Testi Nas\u0131l Yap\u0131l\u0131r?<\/h2>\n<p>IGF-1 ( Somatomedin C), 15. dk. testi, uygun biyolojik \u00f6rnek al\u0131nd\u0131ktan sonra laboratuvar\u0131n belirledi\u011fi y\u00f6ntemle \u00e7al\u0131\u015f\u0131l\u0131r. Numunenin do\u011fru zamanda, uygun kapta ve uygun ta\u015f\u0131ma ko\u015fullar\u0131nda ula\u015ft\u0131r\u0131lmas\u0131 test kalitesi a\u00e7\u0131s\u0131ndan \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li><strong>Numune T\u00fcr\u00fc:<\/strong> Serum<\/li>\n<li><strong>Numune Kab\u0131:<\/strong> Sar\u0131 Kapak<\/li>\n<li><strong>\u00c7al\u0131\u015fma G\u00fcn\u00fc:<\/strong> Her g\u00fcn<\/li>\n<li><strong>\u00d6nemli Kriter:<\/strong> \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.<\/li>\n<li><strong>Raporlama Tarihi:<\/strong> 2 g\u00fcn sonra 18:00<\/li>\n<\/ul>\n<ul>\n<li><strong>Numune Tipi:<\/strong> Ven\u00f6z kan (serum)<\/li>\n<li><strong>Numune Alimi:<\/strong> Koldan standart kan alma islemiyle yaklasik 5 mL kan alinir.<\/li>\n<li><strong>Y\u00f6ntem:<\/strong> Imm\u00fcnoassay (kemil\u00fcminesans)<\/li>\n<li><strong>Sonu\u00e7 S\u00fcresi:<\/strong> 1\u20132 is g\u00fcn\u00fc<\/li>\n<\/ul>\n<p>Baz\u0131 durumlarda \u00f6rnek kalitesi, numune miktar\u0131, ta\u015f\u0131ma s\u00fcresi veya teknik tekrar gereksinimi raporlama s\u00fcresini ve sonucun g\u00fcvenilirli\u011fini etkileyebilir.<\/p>\n<h2>IGF-1 ( Somatomedin C), 15. dk. Testi Ka\u00e7 G\u00fcnde \u00c7\u0131kar?<\/h2>\n<p>Mevcut laboratuvar bilgisine g\u00f6re bu test i\u00e7in raporlama s\u00fcresi: <strong>2 g\u00fcn sonra 18:00<\/strong> \u015feklindedir.<\/p>\n<p>Numunenin kabul zaman\u0131, laboratuvar\u0131n \u00e7al\u0131\u015fma plan\u0131, resmi tatiller veya gerekti\u011finde tekrar \u00e7al\u0131\u015fma gibi etkenler sonucu etkileyebilece\u011fi i\u00e7in en g\u00fcncel bilgi rapor tarihi \u00fczerinden de\u011ferlendirilmelidir.<\/p>\n<h2>Referans De\u011ferleri ve Sonu\u00e7lar\u0131n De\u011ferlendirilmesi<\/h2>\n<p>IGF-1 referans degerleri <strong>yasa ve cinsiyete g\u00f6re<\/strong> b\u00fcy\u00fck farklilik g\u00f6sterir:<\/p>\n<h3>Erkekler (ng\/mL)<\/h3>\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Yas<\/th><th>Deger Araligi<\/th><\/tr><\/thead><tbody><tr><td>0\u20133 yas<\/td><td>18 \u2013 229<\/td><\/tr><tr><td>4\u20138 yas<\/td><td>44 \u2013 310<\/td><\/tr><tr><td>9\u201311 yas<\/td><td>56 \u2013 452<\/td><\/tr><tr><td>12\u201315 yas<\/td><td>127 \u2013 903<\/td><\/tr><tr><td>16\u201320 yas<\/td><td>175 \u2013 660<\/td><\/tr><tr><td>21\u201330 yas<\/td><td>116 \u2013 358<\/td><\/tr><tr><td>31\u201340 yas<\/td><td>91 \u2013 246<\/td><\/tr><tr><td>41\u201350 yas<\/td><td>78 \u2013 220<\/td><\/tr><tr><td>51\u201360 yas<\/td><td>68 \u2013 200<\/td><\/tr><tr><td>61\u201370 yas<\/td><td>56 \u2013 188<\/td><\/tr><tr><td>>70 yas<\/td><td>45 \u2013 170<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<h3>Kadinlar (ng\/mL)<\/h3>\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Yas<\/th><th>Deger Araligi<\/th><\/tr><\/thead><tbody><tr><td>0\u20133 yas<\/td><td>18 \u2013 229<\/td><\/tr><tr><td>4\u20138 yas<\/td><td>44 \u2013 328<\/td><\/tr><tr><td>9\u201311 yas<\/td><td>73 \u2013 508<\/td><\/tr><tr><td>12\u201315 yas<\/td><td>150 \u2013 842<\/td><\/tr><tr><td>16\u201320 yas<\/td><td>123 \u2013 550<\/td><\/tr><tr><td>21\u201330 yas<\/td><td>100 \u2013 330<\/td><\/tr><tr><td>31\u201340 yas<\/td><td>80 \u2013 230<\/td><\/tr><tr><td>41\u201350 yas<\/td><td>68 \u2013 210<\/td><\/tr><tr><td>51\u201360 yas<\/td><td>58 \u2013 190<\/td><\/tr><tr><td>61\u201370 yas<\/td><td>48 \u2013 175<\/td><\/tr><tr><td>>70 yas<\/td><td>38 \u2013 160<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<p>> *Not: Referans degerleri laboratuvarlar ve kullanilan kitlere g\u00f6re degisebilir. Yas ve cinsiyete uygun referans araliklarinin kullanilmasi esastir.*<\/p>\n<p>Referans bilgileri; kullan\u0131lan y\u00f6ntem, ya\u015f grubu, biyolojik \u00f6rnek tipi ve laboratuvar standard\u0131na g\u00f6re de\u011fi\u015febilece\u011finden, rapor \u00fczerinde yer alan laboratuvar yorumu esas al\u0131nmal\u0131d\u0131r.<\/p>\n<h2>IGF-1 ( Somatomedin C), 15. dk. Sonucu Nas\u0131l Yorumlan\u0131r?<\/h2>\n<p>Test sonucu tek ba\u015f\u0131na kesin tan\u0131 koydurmaz. Sonu\u00e7; klinik bulgular, di\u011fer laboratuvar verileri ve gerekli g\u00f6r\u00fcld\u00fc\u011f\u00fcnde ek incelemeler ile birlikte de\u011ferlendirilir.<\/p>\n<h3>IGF-1 Y\u00fcksekligi<\/h3>\n<ul>\n<li><strong>Akromegali<\/strong> (GH salgilayan hipofiz adenomu)<\/li>\n<li><strong>Gigantizm<\/strong> (\u00e7ocuklarda)<\/li>\n<li>Gebelik (hafif artis)<\/li>\n<li>Erken puberte<\/li>\n<li>Obezite (bazen hafif y\u00fcksek)<\/li>\n<li>Hipoglisemi (nadir)<\/li>\n<\/ul>\n<h3>IGF-1 D\u00fcs\u00fckl\u00fcg\u00fc<\/h3>\n<ul>\n<li><strong>GH eksikligi<\/strong> (konjenital veya edinilmis)<\/li>\n<li>Hipopit\u00fcitarizm<\/li>\n<li>Maln\u00fctrisyon ve a\u00e7lik<\/li>\n<li>Kronik karaciger hastaligi (IGF-1 \u00fcretim yeri karaciger oldugu i\u00e7in)<\/li>\n<li>Kronik b\u00f6brek hastaligi<\/li>\n<li>Hipotiroidizm<\/li>\n<li>Kontrols\u00fcz diyabet (Tip 1)<\/li>\n<li>Laron sendromu (GH resept\u00f6r defekti \u2014 GH y\u00fcksek ama IGF-1 d\u00fcs\u00fck)<\/li>\n<li>Anoreksiya nervoza<\/li>\n<\/ul>\n<p>\u00d6zellikle s\u0131n\u0131rda, d\u00fc\u015f\u00fck d\u00fczeyli veya beklenmeyen sonu\u00e7larda klinik korelasyon gerekir. Gerekti\u011finde tekrar test, panel de\u011ferlendirmesi veya ek laboratuvar incelemeleri planlanabilir.<\/p>\n<h2>Testin S\u0131n\u0131rl\u0131l\u0131klar\u0131<\/h2>\n<p>Her laboratuvar testinde oldu\u011fu gibi bu incelemenin de baz\u0131 s\u0131n\u0131rl\u0131l\u0131klar\u0131 vard\u0131r. Sonu\u00e7; \u00f6rnek kalitesi, \u00f6rnekleme zaman\u0131, ta\u015f\u0131ma ko\u015fullar\u0131 ve klinik ba\u011flamdan etkilenebilir.<\/p>\n<ul>\n<li>Tek bir laboratuvar sonucu, klinik \u00e7er\u00e7eve d\u0131\u015f\u0131nda eksik yorumlanabilir.<\/li>\n<li>Uygun olmayan numune kalitesi sonucun g\u00fcvenilirli\u011fini azaltabilir.<\/li>\n<li>Gerekti\u011finde ek testler olmadan tek ba\u015f\u0131na karar vermek yan\u0131lt\u0131c\u0131 olabilir.<\/li>\n<\/ul>\n<h2>Olas\u0131 Riskler<\/h2>\n<p>Risk \u00e7o\u011funlukla numune alma ve numune y\u00f6netimi s\u00fcreci ile ili\u015fkilidir. Testin kendisinden \u00e7ok, \u00f6rne\u011fin al\u0131nmas\u0131 ve uygun ko\u015fullarda \u00e7al\u0131\u015f\u0131lmas\u0131 \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li>Kan alma islemi g\u00fcvenlidir; hafif agri, morarma olabilir.<\/li>\n<li>IGF-1, GH&#8217;nin aksine <strong>g\u00fcn i\u00e7inde stabil<\/strong> d\u00fczeyde bulunur; bu nedenle GH eksikligi ve akromegali taramasinda ilk basamak test olarak tercih edilir.<\/li>\n<li><strong>Yasa ve cinsiyete uygun referans araliklari<\/strong> kullanilmalidir; \u00f6zellikle puberte d\u00f6neminde degerler \u00e7ok y\u00fcksek olabilir (fizyolojik).<\/li>\n<li>D\u00fcs\u00fck IGF-1 her zaman GH eksikligi anlamina gelmez; maln\u00fctrisyon, karaciger hastaligi ve hipotiroidizm dislanmalidir.<\/li>\n<li>Akromegali tedavi takibinde IGF-1 normalizasyonu tedavi basarisinin g\u00f6stergesidir.<\/li>\n<li>GH eksikligi s\u00fcphesinde IGF-1 normal olsa bile GH stim\u00fclasyon testleri gerekebilir (d\u00fcs\u00fck duyarlilik).<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>IGF-1 ( Somatomedin C), 15. dk. Laboratuvar Bilgileri Yeni Kod: BIO4140 SUT Kodu: L103800 Eski Kod: HR1140 Kategori: Biyokimya Numune T\u00fcr\u00fc: Serum Numune Kab\u0131: Sar\u0131 Kapak \u00c7al\u0131\u015fma G\u00fcn\u00fc: Her g\u00fcn \u00d6nemli Kriter: \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r. Raporlama Tarihi: 2 g\u00fcn sonra 18:00 IGF-1 ( Somatomedin C), 15. [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":5,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"test_category":"Biyokimya","test_kodu":"BIO4140","numune_turu":"Serum","numune_kabi":"Sar\u0131 Kapak","calisma_gunu":"Her g\u00fcn","onemli_kriter":"\u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.","raporlama_tarihi":"2 g\u00fcn sonra 18:00","numune_red_kriterleri":"","aktarim_kodu":"","loinc_kodu":"","sut_kodu":"L103800","akredite":"","numune_miktari":"","alternatif_ornek":"","numune_alinma_sekli":"","stabilite_ozellikleri":"","calisma_yontemi":"","test_bilgisi":"","footnotes":""},"class_list":["post-3173","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/comments?post=3173"}],"version-history":[{"count":4,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3173\/revisions"}],"predecessor-version":[{"id":8910,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3173\/revisions\/8910"}],"up":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/5"}],"wp:attachment":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/media?parent=3173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}